Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.
Ankylosing Spondylitis Research and the Cell Biology Underneath It
Ankylosing spondylitis (AS) is a chronic inflammatory arthropathy affecting primarily the axial skeleton, with a well-established genetic association to HLA-B27. The immunological mechanism involves innate-adaptive immune crosstalk, Th17 pathway activation, and inflammatory cytokine production that drives enthesitis and new bone formation. For researchers developing therapeutic candidates in this space — IL-17A inhibitors, IL-23 blockade, JAK inhibitors, and novel biologics — access to well-characterized AS donor cells is central to the translational work.
OrganaBio maintains a portfolio of ankylosing spondylitis donors with clinical annotation supporting research and drug screening applications. This material is available for research use only (RUO).
AS Immune Biology: What You’re Working With
The key immunological features of AS that make donor cell biology relevant to therapeutic programs:
Th17/IL-17 axis
AS is one of the conditions where Th17 pathway dysregulation has been most clearly demonstrated. Elevated serum IL-17A, expanded circulating Th17 cells, and IL-17A expression at the enthesis all characterize active disease. AS donors provide PBMCs where Th17 frequencies and functional responses can be measured in a disease-relevant context rather than extrapolated from healthy donor cells.
HLA-B27 association
HLA-B27 is present in approximately 90% of AS patients (versus 6–8% of the general population) and is the strongest genetic risk factor for the disease. The mechanism connecting HLA-B27 to AS pathogenesis remains an active research area — proposed mechanisms include misfolded protein stress responses, altered peptide presentation, and HLA-B27 homodimer formation activating KIR3DL2+ NK cells. HLA-B27 typing data is available for OrganaBio AS donors.
Innate immune involvement
Beyond Th17 cells, AS pathogenesis involves innate lymphoid cells (ILC3s), NK cells, and mast cells. Circulating ILC3 frequencies are elevated in active AS. Mucosal-associated invariant T (MAIT) cells show altered phenotype and function in AS patients. For programs targeting innate immune components, AS donor PBMCs provide the relevant cellular context.
TNF and IL-23
TNF blockade was the first effective biologic therapy for AS and remains standard of care, but a significant proportion of patients are inadequate responders. IL-23 inhibitors have demonstrated efficacy in AS, positioning IL-23 as an upstream driver of the Th17 response in this disease. AS donor cells allow ex vivo pharmacodynamic studies characterizing how candidate molecules affect these pathways in disease-relevant cells.
Donor Characterization and Clinical Annotation
OrganaBio AS donors are characterized with clinical annotation relevant to translational research. Standard annotation includes:
- Confirmed AS diagnosis (clinical criteria, imaging confirmation where available)
- Disease activity assessment at time of collection (BASDAI score or clinical characterization)
- HLA-B27 typing status
- Current treatment status and medication history (biologic-naive, biologic-experienced, NSAID use)
- Disease duration and disease course characteristics
- Relevant comorbidities (IBD association, psoriasis, uveitis history)
Treatment status at collection is particularly relevant for ex vivo pharmacodynamic work — biologic-naive donors preserve the intact disease phenotype without drug-induced immune normalization.
Available Products
AS donor material is available in cryopreserved format and includes:
- Whole PBMCs (mononuclear cell fraction)
- Leukopak-derived material where collection volume supports it
- Subset-enriched fractions available on request depending on donor and volume
All AS donor material is for research use only and is not suitable for clinical administration or GMP manufacturing without additional qualification.
Ordering and Availability
AS donor availability varies based on current inventory and active donor pool status. OrganaBio maintains an active disease-state program with ongoing enrollment. Contact OrganaBio’s scientific team to discuss your specific research requirements, including disease activity, treatment history, HLA typing needs, and cell count requirements. Custom collection can be arranged for studies requiring defined clinical parameters not available from current inventory.
Source from OrganaBio
FDA-registered. ISO 7 cGMP. Ships anywhere in the US.
Request Disease-State PBMCsView PBMC ProductsFrequently Asked Questions
Why are PBMC donors with ankylosing spondylitis used in immunology research?
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis with a strong HLA-B27 association — approximately 90% of AS patients carry the HLA-B27 allele, compared to 6-8% in the general population. This genetic link makes AS an important model for studying HLA class I-restricted immune responses, autoreactive T cell mechanisms, and the role of innate immune cells (particularly ILC3s and neutrophils) in spondyloarthritis. PBMC donors with active or well-characterized AS provide a biologically relevant cell source for assay development, drug screening, and mechanistic studies of TNF-α pathways, IL-17/IL-23 axis responses, and CD8+ T cell activation in an HLA-B27 positive context.
How is HLA-B27 status documented for AS donors in OrganaBio’s pool?
OrganaBio performs 6-digit NGS HLA typing on all qualified donors, which provides resolution at the allele level — distinguishing between HLA-B*27:02, B*27:05, B*27:07, and other B27 subtypes that differ in their association with disease and immune function. HLA-B27 status and subtype are documented on the donor’s qualification record and reflected in the COA for lots from B27-positive donors. For researchers who require specific HLA-B27 subtypes — for example, B*27:05 (most prevalent in Northern European AS patients) versus B*27:02 (more common in Mediterranean populations) — donor selection by subtype is available. Contact the OrganaBio team with HLA requirements before requesting a quote.
What immune cell populations are most relevant in AS donor PBMCs for research use?
In AS donor PBMCs, the most studied populations include: CD8+ cytotoxic T cells (particularly HLA-B27-restricted populations relevant to self-peptide presentation hypotheses), CD4+ Th17 cells (IL-17 producing, relevant to the IL-23/Th17 axis that is a therapeutic target), regulatory T cells (Tregs, which are altered in frequency and function in AS), and innate lymphoid cells type 3 (ILC3s, which produce IL-17 and IL-22). Monocyte activation markers are also studied in AS given the elevated TNF-α environment. When ordering AS donor PBMCs, specifying which populations are most relevant to your assay allows OrganaBio to provide donor-level subset data to help you select material with appropriate cell frequencies.
Are OrganaBio’s AS donor PBMCs appropriate for clinical-grade use?
Disease-state donor PBMCs from OrganaBio, including AS donors, are for research use only (RUO). They are not GMP-grade and should not be used as clinical-grade starting material for manufacturing cell therapies intended for human use. For autoimmune disease applications in cell therapy, clinical programs typically use the patient’s own apheresis product as GMP starting material — not a third-party disease-state donor pool. OrganaBio’s AS donor material is appropriate for in vitro research, drug screening, biomarker development, assay qualification, and mechanistic studies where research-grade donor cells are sufficient.
What clinical annotations does OrganaBio provide for AS donors?
OrganaBio provides clinical annotation at the donor level covering: confirmed AS diagnosis (diagnosis date, diagnostic criteria used), HLA-B27 status and subtype, disease activity indicators (BASDAI score where available, current and prior biologic therapy exposure, time since last dose), relevant comorbidities, and current medication status at collection. Donors who are DMARD-naive, on stable biologic therapy, or post-biologics can be specified depending on your research needs. For assays where TNF inhibitor exposure or IL-17A pathway targeting is a variable, donor selection by treatment history is available. Contact the OrganaBio team with your clinical annotation requirements when requesting AS donor material.
